ClinicalTrials.Veeva

Menu

Study of Tumor-shrinking Decoction (TSD) to Treat Symptomatic Uterine Fibroids

The University of Hong Kong (HKU) logo

The University of Hong Kong (HKU)

Status and phase

Completed
Phase 3

Conditions

Leiomyoma

Treatments

Drug: TSD

Study type

Interventional

Funder types

Other

Identifiers

NCT02189083
HKU-SCM-TSD2014
HMRF-11121841 (Other Grant/Funding Number)

Details and patient eligibility

About

On the basis of empirical evidence and clinical practice, the investigators have developed a formula called Tumor-shrinking Decoction (TSD) used in the treatment of uterine fibroids (UFs). The investigators preliminary clinical observation has demonstrated the benefits of TSD in improving UFs.

TSD is composed of 15 individual Chinese medicines: Astragalus Membranaceus, Semen Coicis, Poria, Curcuma longa L, and Fritillaria Thunbergii Miq, Cassia twig, Pollen typhae, Resina draconis, Lithospermum erythrorhizon, Halloysitum Rubrum, Rhizoma Corydalis processed with vinegar, Hirudo, Calcined corrugated sub , Oyster Shell and Laminaria Japonica Aresch.

It is hypothesized that TSD can effectively reduce the fibroid size and improve the symptoms associated with UFs and the greater anti-tumor potency of TSD is associated with higher therapeutic doses.

To test this hypothesis, one 16-week, double-blind, randomized, two-dose trial will be conducted in patients with symptomatic UFs to determine whether the high dose (217 g/day) of TSD could produce significantly greater effects in reducing the fibroid size and improving its related symptoms and biochemical profiles compared to the lower dose (69 g/day).

Full description

Numerous Chinese medicine preparations have been shown to possess therapeutic potential in relieving uterine fibroids (UFs) symptoms and shrinking the volume of fibroids without significant adverse effects, although the clinical efficacy needs to be further confirmed with rigorously designed.On the basis of empirical evidence and clinical practice, the investigators have developed a formula called Tumor-shrinking Decoction (TSD) used in the treatment of UFs. The investigators preliminary clinical observation has demonstrated the benefits of TSD in improving UFs.

TSD is composed of 15 individual Chinese medicines. According to traditional Chinese medicine (TCM) doctrine, most UFs are developed due to the deficiency of vital energy and the stasis of blood, resulting in the formation of pathological massive tissues. Individual Chinese medicines constituting TSD can be classified into three classes based on TCM-defined pharmacological actions: (i) Tonifying qi and resolve phlegm: Astragalus Membranaceus, Semen Coicis, Poria, Curcuma longa L, and Fritillaria Thunbergii Miq; (ii) Resolve stasis, stopping bleeding and relieve pain: Cassia twig, Pollen typhae, Resina draconis, Lithospermum erythrorhizon, Halloysitum Rubrum, Rhizoma Corydalis processed with vinegar; and (iii) Softening hardness and dissipate binds: Hirudo, Calcined corrugated sub , Oyster Shell and Laminaria Japonica Aresch.

Indeed, the investigators previous studies of cultured cells and animals have revealed that TSD robustly inhibits fibroid cell growth and proliferation. The investigators therefore hypothesize that TSD can effectively reduce the fibroid size and improve the symptoms associated with UFs and the greater anti-tumor potency of TSD is associated with higher therapeutic doses.

To test this hypothesis, one 16-week, double-blind, randomized, two-dose trial will be conducted in patients with symptomatic UFs to determine whether the high dose (217 g/day) of TSD could produce significantly greater effects in reducing the fibroid size and improving its related symptoms and biochemical profiles compared to the lower dose (69 g/day).

Enrollment

78 patients

Sex

All

Ages

18 to 52 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Premenopausal women aged 18 to 52 years; and
  2. have a primary diagnosis of symptomatic UFs based on clinical symptoms; and
  3. MRI examination as defined in the International Classification of Diseases (10th edition).

Exclusion criteria

  1. Unstable medical conditions such as serious cardiovascular diseases;
  2. With severe neuropsychiatric disorders;
  3. Combined with adenomyosis or other tumors;
  4. On treatment with Chinese medicine or other natural products in the previous 3 months;
  5. With an allergic history of herbal medicine; or
  6. Being pregnant and lactating women and those who currently use contraception.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

78 participants in 2 patient groups

High dose TSD
Experimental group
Description:
Subjects in this arm receive high dose (217 g/day) TSD for 16 weeks.
Treatment:
Drug: TSD
Low dose TSD
Active Comparator group
Description:
Subjects in this arm receive low dose (69 g/day) TSD for 16 weeks.
Treatment:
Drug: TSD

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems